The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity?

Neuroscience and Biobehavioral Reviews
Florian FreudenbergAndreas Reif

Abstract

Depression is a major psychiatric disorder affecting more than 120 million people worldwide every year. Changes in monoaminergic transmitter release are suggested to take part in the pathophysiology of depression. However, more recent experimental evidence suggests that glutamatergic mechanisms might play a more central role in the development of this disorder. The importance of the glutamatergic system in depression was particularly highlighted by the discovery that N-methyl-D-aspartate (NMDA) receptor antagonists (particularly ketamine) exert relatively long-lasting antidepressant like effects with rapid onset. Importantly, the antidepressant-like effects of NMDA receptor antagonists, but also other antidepressants (both classical and novel), require activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Additionally, expression of AMPA receptors is altered in patients with depression. Moreover, preclinical evidence supports an important involvement of AMPA receptor-dependent signaling and plasticity in the pathophysiology and treatment of depression. Here we summarize work published on the involvement of AMPA receptors in depression and discuss a possible central role for AMPA receptors in the p...Continue Reading

References

Jan 1, 1992·Neuroscience and Biobehavioral Reviews·P WillnerM Papp
Mar 1, 1992·Journal of Clinical and Experimental Neuropsychology·H A SackeimD P Devanand
Aug 21, 1990·European Journal of Pharmacology·R Trullas, P Skolnick
Jan 1, 1996·Brain Research. Molecular Brain Research·P NaylorI C Reid
Jan 1, 1997·Annual Review of Psychology·R C Kessler
Oct 1, 1998·Behavioural Brain Research·R GerlaiZ Jia
Feb 25, 2000·Biological Psychiatry·R M BermanJ H Krystal
Jun 19, 2001·Neuropharmacology·X LiP Skolnick
Nov 10, 2001·Pharmacology, Biochemistry, and Behavior·F BaiP Skolnick
Dec 4, 2001·Pharmacology·Ewa MalatynskaRichard J Knapp
Jan 11, 2002·Neurological Research·Frantisek St'astnýDaniela Jezová
Mar 7, 2002·Proceedings of the National Academy of Sciences of the United States of America·Per SvenningssonPaul Greengard
Apr 18, 2002·European Journal of Pharmacology·Richard J KnappEwa Malatynska
Aug 27, 2002·Nature Neuroscience·D ReiselJ N P Rawlins
Oct 16, 2002·Brain Research Bulletin·Maria Luiza Nunes Mamede RosaElaine Aparecida Del Bel
Jan 16, 2003·Neuropharmacology·Rebeca Martinez-TurrillasJoaquín Del Río
Mar 20, 2003·Behavioural Brain Research·Gernot RiedelJacques Micheau
Jul 25, 2003·The Journal of Physiology·Bertalan K AndrásfalvyJeffrey C Magee
Jan 16, 2004·Pharmacology, Biochemistry, and Behavior·C M Padovan, F S Guimarães
Jan 30, 2004·Fundamental & Clinical Pharmacology·D A SlatteryD J Nutt
Feb 24, 2004·Annual Review of Physiology·Mark L Mayer, Neali Armstrong
Apr 2, 2004·Journal of Neurochemistry·Yongjun QinMarian Joëls
May 5, 2004·The International Journal of Neuropsychopharmacology·Takami SuenagaShigeto Yamawaki
Jun 8, 2004·Current Drug Targets. CNS and Neurological Disorders·Michael J O'NeillEric S Nisenbaum
Jun 24, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gregor HaslerDennis S Charney
Sep 4, 2004·Genes, Brain, and Behavior·O Y VekovischevaE R Korpi
Dec 2, 2004·Nature Reviews. Drug Discovery·Kumlesh K Dev

❮ Previous
Next ❯

Citations

Feb 9, 2017·Brain Research·Oleg I BaryginNatalia N Shestakova
Jul 31, 2019·Journal of Neurochemistry·Dietrich van CalkerTsvetan Serchov
Nov 29, 2015·Neurotoxicity Research·Yousef Tizabi
Mar 19, 2019·Current Psychiatry Reports·Jennifer R Goldschmied, Philip Gehrman
Jul 6, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lena BrundinKeerthi Thirtamara Rajamani
Jun 15, 2020·Molecular Neurobiology·Marta Gordillo-SalasAlbert Adell
Jan 30, 2021·Neural Regeneration Research·Sachchida Nand RaiBrijesh Kumar Singh
Mar 13, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Hui-Qin WangNai-Hong Chen
Mar 14, 2021·Purinergic Signalling·Priscila B RosaAna Lúcia S Rodrigues
May 4, 2021·Frontiers in Pharmacology·Meiying CuiHongzhi Chen
Nov 28, 2017·Journal of Affective Disorders·Jianyang DongXiang Cai
Jun 19, 2021·Biomedit︠s︡inskai︠a︡ khimii︠a︡·E V RadchenkoV A Palyulin
Dec 3, 2020·Sexual Medicine Reviews·Ibrahim A Abdel-Hamid, Omar I Ali
Jul 10, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ya-Ting WangYi Zhang
Aug 27, 2021·Cellular and Molecular Neurobiology·Qing-Lin WuNai-Hong Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Barrel cortex

Here is the latest research on barrel cortex, a region of somatosensory and motor corticies in the brain, which are used by animals that rely on whiskers for world exploration.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Calcium & Bioenergetics

Bioenergetic processes, including cellular respiration and photosynthesis, concern the transformation of energy by cells. Here is the latest research on the role of calcium in bioenergetics.